Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Additional imaging techniques can detect early stage cancers missed by mammograms in women with dense breasts

2.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

3.

EBV Screening Tied to Lower Nasopharyngeal Cancer Mortality Risk

4.

FDA Approves Hemophilia B Second Gene Therapy.

5.

What Kate Middleton Reminds Us About the Role of Privacy in Healing.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot